Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 15 Oct 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 43 Florida 34 New York 21 Colorado 19 Texas 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Regeneron Pharmaceuticals6 Bristol-Myers Squibb4 Merck Sharp & Dohme LLC3 HiFiBiO Therapeutics2 Genentech, Inc.2
State
California43 Florida34 New York21 Colorado19 Texas17
All 43 states
Target enrolment
to

Trials with a site in California

43 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Intratumoral N17350 in Advanced Solid Tumors
NCT07339176Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
Onchilles Pharma Inc
Phase 1/2
275
California, New York, Texas
2026-05-25
Recruiting
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
NCT06887348Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Replimune, Inc.
Observational
50
California
2025-12-12
Active, closed
Shanghai Henlius Biotech
Phase 1
174
California, Florida, Texas, Washington
2025-09-26
By invitation
Regeneron Pharmaceuticals
Phase 2
48
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Active, closed
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
DrugsCobolimab·Dostarlimab
GlaxoSmithKline
Phase 1/2
83
California, Iowa, New Jersey, Ohio, Rhode Island, Wisconsin
2025-03-06
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Recruiting
Regeneron Pharmaceuticals
Phase 3
560
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-09-09
Active, closed
TScan Therapeutics, Inc.
Phase 1
840
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2024-05-06
Recruiting
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
DrugLenvatinib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
178
California, Florida, Kansas, Michigan, Texas, Washington
2024-04-08
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington
2024-04-08
Active, closed
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Ipsen
Phase 1/2
36
California, Connecticut, Tennessee, Virginia
2024-04-03
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
California, Connecticut, Florida, Illinois, Maryland, Minnesota, Missouri, New York
2024-02-26
Active, closed
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Active, closed
Bristol-Myers Squibb
Phase 2
100
Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington
2023-11-06
Active, closed
Amgen
Phase 3
633
California, Indiana, Louisiana, Missouri, New York
2023-11-02
Recruiting
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
Obsidian Therapeutics, Inc.
Phase 1/2
254
California, Florida, Kentucky, New York, Ohio, Pennsylvania, Texas
2023-10-25
Recruiting
CJ Bioscience, Inc.
Phase 1/2
160
California, Pennsylvania
2023-09-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Arkansas, California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts
2023-07-19
Active, closed
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer
DrugTislelizumab
HiFiBiO Therapeutics
Phase 1
83
California, Pennsylvania, Virginia
2023-05-09
Recruiting
Iovance Biotherapeutics, Inc.
Phase 3
670
Alabama, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2023-03-30
Active, closed
Bristol-Myers Squibb
Phase 3
579
Arizona, Arkansas, California, Colorado, Florida, Maryland, Minnesota, Nebraska
2023-03-06
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
California, Colorado, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York
2023-01-16
Active, closed
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
NCT05653882Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
DrugsEtakafusp alfa·Keytruda·Pembrolizumab
Asher Biotherapeutics, Inc.
Phase 1
552
California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2023-01-04
Active, closed
Pfizer
Phase 1
148
Alabama, Arkansas, California, Florida, Louisiana, Massachusetts, Michigan, New Jersey
2022-11-30
Active, closed
Genentech, Inc.
Phase 1
165
California, Colorado, Florida, Georgia, Massachusetts, Missouri, New Jersey, Tennessee
2022-10-20
Active, closed
Jazz Pharmaceuticals
Phase 1
98
California, Colorado, Florida, Illinois, New York, Oklahoma, Pennsylvania, Tennessee
2022-10-10
Active, closed
AstraZeneca
Phase 2
194
California, Florida, Maryland, Tennessee
2022-08-11
Active, closed
BioAtla, Inc.
Phase 1/2
320
California, Georgia, Indiana, New Jersey, New York, Ohio, Oregon, Utah
2022-08-03
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,546
California, Florida, Ohio, Tennessee
2022-07-14
Active, closed
HiFiBiO Therapeutics
Phase 1
72
Arizona, California, Florida, Minnesota, Missouri, Texas, Virginia
2022-03-10
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Tennessee
2021-08-04
Active, closed
Genentech, Inc.
Phase 1
65
California, Colorado, Iowa, Maryland, Missouri, New York, Tennessee
2021-05-13
Recruiting
BioInvent International AB
Phase 1/2
250
California, New York, Pennsylvania
2021-01-25
Active, closed
Novartis Pharmaceuticals
Phase 2
134
California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2020-10-30
Active, closed
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
DrugsVSV-IFNβ-NIS·Cemiplimab
Vyriad, Inc.
Phase 2
87
California, Connecticut, Florida, Louisiana, Minnesota, Montana, New York, Ohio
2020-04-24
Recruiting
Inhibrx Biosciences, Inc
Phase 1/2
340
California, Florida, Georgia, Illinois, Iowa, Kentucky, Michigan, Minnesota
2019-12-10
Active, closed
Bristol-Myers Squibb
Phase 3
790
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Georgia, Illinois
2019-10-28
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Alaska, California, Connecticut, Delaware, Florida, Illinois, Kentucky, Maryland
2019-09-17
Active, closed
ModernaTX, Inc.
Phase 2
267
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2019-07-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2018-09-12
Active, closed
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation
DrugPembrolizumab
Ascentage Pharma Group Inc.
Phase 1/2
230
Arizona, Arkansas, California, District of Columbia, Florida, Missouri, New York, North Carolina
2018-08-29
Active, closed
Bristol-Myers Squibb
Phase 2/3
714
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Maryland
2018-04-11
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/california

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 15 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies with a site in California that also match the filters currently applied.

How many clinical trials are recruiting in California?

13 of the 43 studies on this page are recruiting new participants as of the 15 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 29 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (California), 43 studies
PhaseStudiesRecruitingShare
Phase 1/211625.6%
Phase 110123.3%
Phase 210223.3%
Phase 39220.9%
Observational224.7%
Phase 2/3102.3%

Most active sponsors

Lead sponsors with the most studies (California)
Lead sponsorStudiesRecruiting
Regeneron Pharmaceuticals62
Bristol-Myers Squibb40
Merck Sharp & Dohme LLC30
Genentech, Inc.20
HiFiBiO Therapeutics20
Amgen10
Ascentage Pharma Group Inc.10
Asher Biotherapeutics, Inc.10
AstraZeneca10
BioAtla, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.